TY - JOUR
T1 - Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease
T2 - a systematic review and meta-analysis
AU - Uchino, Motoi
AU - Ikeuchi, Hiroki
AU - Shimizu, Junzo
AU - Ohge, Hiroki
AU - Haji, Seiji
AU - Mizuguchi, Toru
AU - Mohri, Yasuhiko
AU - Yamashita, Chizuru
AU - Kitagawa, Yuichi
AU - Suzuki, Katsunori
AU - Kobayashi, Motomu
AU - Kobayashi, Masahiro
AU - Sakamoto, Fumie
AU - Yoshida, Masahiro
AU - Mayumi, Toshihiko
AU - Hirata, Koichi
AU - Takesue, Yoshio
N1 - Publisher Copyright:
© 2020, Springer Nature Singapore Pte Ltd.
PY - 2021/1
Y1 - 2021/1
N2 - Tumor necrosis factor-alpha inhibitor (TNFi) treatment is effective for ulcerative colitis (UC) and Crohn’s disease (CD). Although several meta-analyses have been performed to evaluate the association between TNFi treatment and surgical morbidity, the results are controversial. We conducted a systematic review and meta-analysis of the prevention of surgical site infection (SSI) after surgery for UC and CD in patients on TNFis, based on literature published between January 2000 and May 2019 (registered on PROSPERO, No. CRD42019134156). Overall, 2175 UC patients in 13 observational studies (OBSs) and 7084 CD patients in 16 OBSs were included. The incidences of incisional (INC) SSI and organ/space (O/S) SSI after surgery for UC were 179/1985 (9.0%) and 176/2175 (8.1%), respectively. TNFi use was not associated with the incidences of INC SSI (odds ratio (OR) 1.04, 95% confidence interval (CI) (0.47–2.32) or O/S SSI (OR 1.85, 95% CI (0.82–4.20)) after surgery for UC. The INC SSI and O/S SSI incidences after surgery for CD were 289/3089 (9.4%) and 526/7,084 (7.4%), respectively. Preoperative TNFi use was not associated with INC SSI (OR 0.98, 95% CI (0.52–1.83)) or O/S SSI incidence (OR 1.09, 95% CI (0.78–1.52)) after surgery for CD. We did not find a significant association between preoperative TNFi use and SSI in surgery for UC or CD.
AB - Tumor necrosis factor-alpha inhibitor (TNFi) treatment is effective for ulcerative colitis (UC) and Crohn’s disease (CD). Although several meta-analyses have been performed to evaluate the association between TNFi treatment and surgical morbidity, the results are controversial. We conducted a systematic review and meta-analysis of the prevention of surgical site infection (SSI) after surgery for UC and CD in patients on TNFis, based on literature published between January 2000 and May 2019 (registered on PROSPERO, No. CRD42019134156). Overall, 2175 UC patients in 13 observational studies (OBSs) and 7084 CD patients in 16 OBSs were included. The incidences of incisional (INC) SSI and organ/space (O/S) SSI after surgery for UC were 179/1985 (9.0%) and 176/2175 (8.1%), respectively. TNFi use was not associated with the incidences of INC SSI (odds ratio (OR) 1.04, 95% confidence interval (CI) (0.47–2.32) or O/S SSI (OR 1.85, 95% CI (0.82–4.20)) after surgery for UC. The INC SSI and O/S SSI incidences after surgery for CD were 289/3089 (9.4%) and 526/7,084 (7.4%), respectively. Preoperative TNFi use was not associated with INC SSI (OR 0.98, 95% CI (0.52–1.83)) or O/S SSI incidence (OR 1.09, 95% CI (0.78–1.52)) after surgery for CD. We did not find a significant association between preoperative TNFi use and SSI in surgery for UC or CD.
KW - Crohn’s disease
KW - Postoperative complications
KW - Surgical site infection
KW - Tumor necrosis factor alpha inhibitor
KW - Ulcerative colitis
UR - https://www.scopus.com/pages/publications/85083463329
UR - https://www.scopus.com/pages/publications/85083463329#tab=citedBy
U2 - 10.1007/s00595-020-02003-9
DO - 10.1007/s00595-020-02003-9
M3 - Review article
C2 - 32277281
AN - SCOPUS:85083463329
SN - 0941-1291
VL - 51
SP - 32
EP - 43
JO - Surgery Today
JF - Surgery Today
IS - 1
ER -